• 1
    Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9: 3541.
  • 2
    Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002; 62: 704714.
  • 3
    Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 18391848.
  • 4
    Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic review. Pediatr Transplant 2010; 14: 603613.
  • 5
    Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004; 77: 769776.
  • 6
    Bartosh SM, Ryckman FC, Shaddy R, Michaels MG, Platt JL, Sweet SC. A national conference to determine research priorities in pediatric solid organ transplantation. Pediatr Transplant 2008; 12: 153166.
  • 7
    Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: Twice daily versus once daily dosing. Am J Transplant 2004; 4: 621625.
  • 8
    Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 25052513.
  • 9
    de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523529.
  • 10
    Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566569.
  • 11
    Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus: Are the formulations truly equivalent? Drugs 2011; 71: 15611577.
  • 12
    Kramer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 26322643.
  • 13
    Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007; 7: 16091615.
  • 14
    Pape L, Heidotting N, Ahlenstiel T. Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. Int J Nephrol 2011; 2011: 126251.
  • 15
    Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol 2013; 69: 189195.
  • 16
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259263.
  • 17
    Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012; 34: 680685.
  • 18
    Min SI, Kim SY, Ahn SH, et al. CYP3A5 *1 allele: Impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 2010; 90: 13941400.
  • 19
    Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrol Dial Transplant 2005; 20: 181188.
  • 20
    Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867870.
  • 21
    Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011; 21: 179184.
  • 22
    Canaparo R, Finnstrom N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007; 34: 11381144.
  • 23
    Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011; 50: 451459.
  • 24
    Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012; 94: 10131019.
  • 25
    Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 27572763.
  • 26
    Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583588.
  • 27
    Uchida J, Kuwabara N, Machida Y, et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: A short-term study on its effects on glucose metabolism. Transplant Proc 2012; 44: 128133.
  • 28
    Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis 2011; 57: 331341.
  • 29
    Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 2012; 94: 377382.
  • 30
    Degi A, Kerti A, Kis E, et al. Cardiovascular risk assessment in children following kidney transplantation. Pediatr Transplant 2012; 16: 564576.